News
Half-year liquidity contract statement for Sartorius Stedim Biotech
Sensorion Will Take Part in a Press Conference Launching the Annual UNESCO Week of Sound
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
EQS-News: Abivax publishes novel data with respect to obefazimod’s anti-inflammatory mechanism of action
Sonova launches Conversation Clear Plus earbuds, expanding into the new category of early entry hearing solutions
Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that
Simulations Plus Reports First Quarter Fiscal 2023 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its first
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, is scheduled to present at the 41st Annual J.P
Poxel Announces Upcoming Participation at Investor Conferences
POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Transgene Announces Financial Calendar for 2023
Regulatory News:
TRANSGENE (Paris: TNG) today announced its financial reporting dates for 2023:
March 16, 2023:
2022 Fiscal Year Results
May 10, 2023:
First
Acadia Healthcare to Present at the 41st Annual J.P. Morgan Healthcare Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference, January 9-12, 2023, at The Westin St. Francis, San
Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
Agilent Technologies Inc. (NYSE: A) today announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique
Premier, Inc. to Report Fiscal 2023 Second-Quarter Results and Host Conference Call on February 7, 2023
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2023 second quarter on Tuesday, February 7, at approximately 6:30 a.m. EST. The company will also
Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San
Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that
ICON plc to Present at the 41st Annual J.P. Morgan Healthcare Conference
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 41st Annual J.P
Poxel Announces its Financial Calendar for 2023
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 41st Annual J.P. Morgan
Dexcom to Present at 41st Annual J.P. Morgan Healthcare Conference
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 41st annual J.P. Morgan Healthcare
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announces it has entered into a settlement agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Premier Inc. to Participate in 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in the 41st Annual J.P. Morgan
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through